Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
167
-
Total 13F shares, excl. options
-
56.7M
-
Shares change
-
+3.57M
-
Total reported value, excl. options
-
$1.57B
-
Value change
-
+$105M
-
Put/Call ratio
-
0.41
-
Number of buys
-
101
-
Number of sells
-
-60
-
Price
-
$27.62
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q2 2023
199 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q2 2023.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 167 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.7M shares
of 61.4M outstanding shares and own 92.42% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.42M shares), BlackRock Inc. (5.01M shares), FARALLON CAPITAL MANAGEMENT LLC (4.51M shares), BVF INC/IL (3.78M shares), STATE STREET CORP (3.55M shares), VANGUARD GROUP INC (3.15M shares), JOHNSON & JOHNSON (2.45M shares), COWEN AND COMPANY, LLC (1.66M shares), Cormorant Asset Management, LP (1.5M shares), and PERCEPTIVE ADVISORS LLC (1.47M shares).
This table shows the top 167 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.